The Human Papillomavirus (HPV) is of global importance as it is the most common sexually-transmitted infection (STI) in the United States (Centers for Disease Control & Prevention [CDC], 2014a). It is estimated that 630 million people are affected by HPV worldwide (World Health Organization [WHO], 2014a). The purpose of this HPV educational program was to increase family providers' knowledge about HPV and the HPV vaccine to allay common concerns and fears. Aggregate data with de-identifiable patient information was used in a Power Point presentation that was presented to family medical providers. Providers were asked for their opinions and feedback at the end of the presentation to evaluate the program. Aggregate information with de-identifiable data will be obtained in one to three months after the presentation to see if HPV vaccination rates have increased at the community health center. The global implications of the HPV vaccine are enormous. It is an important public health problem that needs immediate attention. Disseminating information and creating awareness about HPV and the HPV vaccine is of paramount importance.
Introduction
Most sexually active women and men will be infected with HPV at some point in their lives. The peak time for acquiring infection for both women and men is shortly after becoming sexually active. HPV is sexually transmitted, but penetrative sex is not required for transmission. HPV is so common and transmissible that having just one sexual partner often can result in infection (World Health Organization, [WHO], 2014a) . HPV is associated with a significant burden of disease, and has been linked to several cancers such as, vaginal, vulva, penis, anogenital, oropharyngeal/head and neck cancers, as well as genital warts (Giuliano et al., 2011) . It causes cervical cancer, which is the most common HPV-associated cancer in women (WHO, 2014b) . It is also the fourth most common cancer in women, with an estimated 266,000 deaths and 528,000 new cases in 2012 (WHO, 2014b) . Adolescents have the highest prevalence of HPV in the United States, and it is estimated that nearly all sexually active Americans may be infected by the HPV virus in their lifetime (CDC, 2014b) . It is posited that males carry a high burden of the HPV infection and associated cancers, and play a huge role in transmitting the virus to females (Giuliano, Anic, & Nyitray, 2010) . There are many barriers to receiving the HPV vaccine. Some include lack of information regarding the diseases caused by HPV infections and the HPV vaccine, parental belief that the vaccine may harm the future reproductive capabilities of young women, belief that the vaccine is unnecessary, especially for males, and lack of provider recommendation (Hendry, Lewis, Clements, Damery, & Wilkinson, 2013) . Some other barriers include parental belief that vaccine promotes and condones promiscuity or early sexual activity, and the erroneous perceived benefit that HPV vaccination eliminates the need for cervical cancer screening (Vamos, McDermott, & Daley, 2008) . Others include parental belief that their son or daughter is not sexually active and therefore no urgency is warranted, the child is too young to be vaccinated against HPV, the cost of the vaccine, safety concerns, and the side effects of the vaccine (National Institute of Health, 2014). Prophylactic vaccines have the greatest impact when administered prior to disease exposure. Therefore, HPV vaccination for adolescent boys and girls prior to sexual debut will be extremely beneficial in preventing HPV. The use of vaccines has been the greatest public health achievement of the 20 th century (CDC, 2011) , and the best chance of avoiding HPV is through vaccination. Secondary prevention includes screening and treatment of pre-cancer (Dunne & Park, 2013) . The HPV vaccines do not protect against all HPV types, so it is important that women continue to get screened for cervical cancer, even after receiving all 3 doses of the HPV vaccine (CDC, 2014a) . The HPV vaccine is not being used to its full potential, although it was approved for use in females in the United States in 2006 (Palefsky, 2010) . There are two prophylactic HPV vaccines that are safe and highly efficacious. The first of the two commercially available HPV vaccines are the bivalent Cervarix vaccine that targets HPV types 16 and 18 which cause about 70% of all cervical cancer. The quadrivalent Gardasil vaccine targets HPV types 6 and 11, which is responsible for 90% of genital warts (Hariri, Markowitz, Dunne, & Unger, 2013) . Girls and boys ages 11 or 12 years old should get vaccinated. It is recommended to give catch-up vaccines for males through age 21 and for females through age 26, if they were without prior vaccination when they were younger (CDC, 2014a). The purpose of this educational program is to increase family providers' knowledge about HPV and the HPV vaccine, to allay common concerns and fears, with the hope that providers will offer the HPV vaccine to the age-appropriate population.
Methods
A letter of permission was obtained from the Chief Medical Officer, Dr. Anthony Amofah, at Community Health of South Florida, Inc. (CHI) to conduct an educational session about HPV and HPV vaccine with the family medical providers in a group setting. A letter of support to obtain de-identifiable patient information was obtained from the Risk Manager/Privacy Officer at CHI, Mr. Juan Reyes. Aggregate data with de-identifiable patient information was obtained from the Manager of Management Information Systems (MIS), Mr. Joseph Rabaonary, in order to create a graphical representation of HPV vaccination rate at the community health center. This information was placed into a PowerPoint presentation that was presented to a group of family medical providers, and this is included at the end of this paper. An informational sheet was created, at The University of Alabama IRB's request, to provide to family medical providers at the educational session. At the end of the informational session, providers were asked 4 questions in order to evaluate the educational program. The educational evaluation questions are specific and used to help evaluate the program. The questions are:
1. Do you think that you will be more willing to offer the HPV vaccine? If not, why? 2. What are some barriers that you still face with offering the HPV vaccine? 3. What additional information do you think should be included in this educational program?
4. What was something(s) new that you learned from this HPV presentation? One to three months after the educational program, aggregate data with de-identifiable information will be obtained to see if HPV vaccination rates have increased at the community health center.
Participants/Sample
The educational program was used with family medical providers in a group setting at the clinical site. There were no patients used with the educational program and, therefore, it was unnecessary to obtain consent. IRB approval was obtained from the University of Alabama to use the educational program with a group of family medical providers.
Intervention
An in-service educational program about HPV and the HPV vaccine was presented with one group of family medical providers at the clinical site. Statistics were presented about HPV, different HPV-related diseases, types of HPV vaccines, barriers to vaccination, cost of the vaccine, and suggestions to increase vaccination adherence. Deidentifiable information was also presented on age-appropriate males versus females who were eligible to receive the vaccine, and those who actually received the HPV vaccine from August 2013 to July 2014. The educational session with the group of family medical providers lasted one hour. At the end of the educational session, providers were asked 4 questions to evaluate the educational program.
Measures
I asked the group of family medical providers 4 questions to evaluate the educational program. The group of family medical providers was also asked for feedback to evaluate my educational program.
Results
The following tables and graphs depict the age appropriate males and females who were eligible for the HPV vaccine and those who received the vaccine. Table 1 depicts aggregate data for patients who were eligible for the HPV vaccine. There were significantly more eligible females than males who were seen at the clinical site every month. There were 17,275 females and 14,942 males who were eligible for the HPV vaccine from 8/2013 to 7/2014. The graph depicts the greatest number of patients who received the vaccine was in the month of March 2014 and the smallest number of patients was in September 2013. Although there were more female than male patients who were eligible for the vaccine, there were more males who received the HPV vaccine. Table 3 shows aggregate data for patients eligible for the HPV vaccine from January 2015 to May 2015. The greatest number of eligible patients was in May 2015 and the smallest number was in January 2015. The graph depicts a graphical representation of patients who were eligible for the HPV vaccine from January 2015 to May 2015. There were more female than male patients who were eligible for the vaccine monthly. The greatest number who was eligible was in May, 2015, and the smallest number was in January, 2015. Table 4 and figure 4 show patients at the clinical site who received the HPV vaccine from January 2015 to May 2015. Family medical providers were targeted as they are recognized as one of the most influential factors in an individual's or parent's willingness to accept the vaccine (Wong, Lee, Ngai, Chor, & Chan, 2013) . Health care providers should be well-informed about HPV vaccination, and recognize that the strength of their recommendation to patients will foster appropriate HPV vaccination uptake (Rosenthal, Weiss, Zimet, Ma, Good, & Vichnin, 2011 
Limitations
There were 18 medical providers who attended my presentation, and these included Pediatricians and school-based providers. The successful uptake of HPV vaccine is of paramount importance in preventing cervical cancer and other HPV-related cancers, and a provider's recommendation is very powerful in fostering said uptake (Malo, Hassani, Staras, Shenkman, Giuliano & Vadaparampil, 2013) . The de-identifiable information that I obtained was for patients at Doris Ison Health Center, which is the largest of the10community health centers. This information does not reflect information from other smaller satellite clinics. There was insufficient time to gather sufficient data as the aggregate data was collected for 1 to 3 months after the presentation of the HPV educational program. Despite these limitations, the educational program can be used in other community health centers to educate family medical providers and help improve HPV vaccine initiation and completion with age-appropriate population.
